[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362223-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-362223-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","neoadjuvant-chemoradiotherapy-plus-sintilimab-in-proficient-mismatch-repair-locally-advanced-rectal-cancer-with-intermediatehigh-immunoscore-silar-a-single-arm-phase-ii-trial","Neoadjuvant chemoradiotherapy plus sintilimab in proficient mismatch repair locally advanced rectal cancer with intermediate/high-immunoscore (SILAR) - a single-arm phase II trial","","Neoadjuvant chemoradiotherapy (CRT) is evaluated for locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR), focusing on patients stratified by intermediate or high Immunoscore. This single-arm phase II trial enrolled 46 treatment-naïve patients (T3–4N0M0 or T1–4N+M0). All received mFOLFOX6 plus long-course radiotherapy (50 Gy/25 fractions) followed by surgery, with sintilimab added during CRT. Pathologic complete response reached 65.2%, exceeding the prespecified primary endpoint, with high Immunoscore showing 85.7%. R0 resection was 97.8%, ORR 93.5%, leukopenia was common, and grade 3 treatment-related events occurred in 15.2%, indicating favorable efficacy and acceptable safety.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/neoadjuvant-chemoradiotherapy-plus-sintilimab-in-proficient-mismatch-repair-locally-advanced-rectal-cancer-with-intermediatehigh-immunoscore-silar-a-single-arm-phase-ii-trial/362223/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/neoadjuvant-chemoradiotherapy-plus-sintilimab-in-proficient-mismatch-repair-locally-advanced-rectal-cancer-with-intermediatehigh-immunoscore-silar-a-single-arm-phase-ii-trial/362223.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What trial design and patient population were included?","Question",{"text":63,"@type":64},"The study is a single-arm phase II trial enrolling 46 treatment-naïve patients with histologically confirmed LARC (T3–4N0M0 or T1–4N+M0) stratified as having intermediate or high Immunoscore and pMMR.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the treatment delivered, and when was sintilimab added?",{"text":68,"@type":64},"Patients received six cycles of mFOLFOX6 plus long-course radiotherapy (50 Gy in 25 fractions) followed by surgery. Sintilimab was added during CRT during the 2nd to 6th cycle.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the primary efficacy results?",{"text":72,"@type":64},"The primary endpoint, pathologic complete response (pCR), was 65.2% (30/46, 95% CI: 49.7–78.6), with higher pCR in high Immunoscore (85.7%) than intermediate Immunoscore (61.5%).",{"name":74,"@type":61,"acceptedAnswer":75},"What safety outcomes were reported?",{"text":76,"@type":64},"The most common treatment-related adverse event was leukopenia (69.6%, 32/46). Grade 3 TRAEs occurred in 15.2% (7 patients), and postoperative complications occurred in four patients, all grade ≤2.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},362223,1790148465,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Article [https://doi.org/10.1038/s41467-025-65162-8](https://doi.org/10.1038/s41467-025-65162-8)  \nNeoadjuvant chemoradiotherapy plus sintilimab in proﬁcient mismatch repair locally advanced rectal cancer with intermediate/high-immunoscore (SILAR):  \na single-arm phase II trial  \nReceived: 25 November 2024  \n\n| Accepted: 8 October 2025 |\n| --- |\n| |\n| Check for updates |\n\nXiaobin Zheng 1,2,3,4, Huashan Liu 1,2,3,4, Lishuo Shi1,2,3,4, Ziwei Zeng  Xingwei Zhang1,2,3, Shuangling Luo1,2,3, Yonghua Cai1,2,3, Ze Li1,2,3, Zhanzhen Liu1,2,3, Yujie Hou1,2,3, Zuli Yang1,2,3, Xiaowen He1,2,3, Jia Ke1,2,3, Liang Huang1,2,3,5 , Yanxin Luo 1,2,3,5  & Liang Kang 1,2,3,5   \n1,2,3,4  \n,  \nThere is an urgent need to identify those who may beneﬁt from immunotherapy-based chemoradiotherapy (CRT) for patients with locally advanced rectal cancer (LARC) with proﬁcient mismatch repair (pMMR). This single-arm, phase-II trial(NCT05450029), enrolled46treatment-naïve patients with histologically conﬁrmed T3–4N0M0 or T1–4N+M0 LARC with intermediate or high Immunoscore. Patients received 6 cycles of mFOLFOX6 and longcourse radiotherapy (50 Gy in 25 fractions) followed by surgery. Sintilimab was added during CRT (2nd-6th cycle). The primary endpoint, pathologic complete response (pCR) rate, was 65.2%[30/46, 95%CI: 49.7–78.6], with 85.7%(6/7) in high and 61.5%(24/39) in intermediate Immunoscore, meeting the prespeciﬁed primary endpoint. Secondary endpoints included R0 resection rate (97.8%), the clinical tumor response (ORR 93.5%), the complication rate and safety, 3-year event-free survival rate, and 3-year overall survival rate (immature). The most common treatment related adverse event (TRAE) was leukopenia (69.6%, 32/46). The TRAE of Grade 3 occurred in 7 patients (15.2%). Four patients had postoperative complications (all grade ≤2). Here, we showed that PD-1 blockade combined with long-course CRT yielded promising therapeutic effects with a favorable pCR rate and acceptable safety proﬁle among patients with intermediate/high-Immunoscore pMMR LARC.  \nDeﬁcient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) has been recognized as particularly promising indicators of responsiveness to immune checkpoint inhibitors (ICIs) across different types of cancers, including colorectal cancers (CRC)1. Recent studies have shown that in MSI-H and dMMR locally advanced rectal cancer  \n(LARC), the application of immunotherapy has achieved a pCR rate as high as 60–88%2,3. This heralds a promising future for implementing  \norgan-preservation strategies after neoadjuvant immunotherapy4,5.  \nHowever, the overall clinical response rate to ICIs in MSI CRC tumors is only 60–70%2,3. In other words, MSI-H might not be able to  \nA full list of afﬁliations appears at the end of the paper. e-mail: [huangl75@mail.sysu.edu.cn](huangl75@mail.sysu.edu.cn); [luoyx25@mail.sysu.edu.cn](luoyx25@mail.sysu.edu.cn); [kangl@mail.sysu.edu.cn](kangl@mail.sysu.edu.cn)  \nfully represent the immune-active status within tumor tissues. The Immunoscore test is the ﬁrst internationally validated standardized assay for quantifying the immune inﬁltrate6,7, providing a reliable evaluation of the natural immune reaction at the tumor site. It is a digital pathology-based assay on the basis of the quantiﬁcation ofCD3+ and CD8+ lymphocytes at both the invasive margin and the core of the tumor8. This method quantiﬁes the densities of both cell types in both regions, establishing a scoring system ranging from low to high immune cell densities9. Notably, an Immunoscore biopsy (ISB) performed at diagnosis has been indicated useful to predict the response to chemoradiotherapy (CRT) in LARC patients, independent of MSI status10,11. An intermediate or high Immunoscore is associated with a more favorable response to CRT, compared to a low one11. Recently, ISB has been further validated as a biomarker to predict both local regrowth and distant metastasis, indicating its clinical utility in selecting L","cbCaicL4fg30EKEQ","https://ap.wps.com/l/cbCaicL4fg30EKEQ","pdf",1343278,"English","# Background and rationale\n# Study design and patient selection\n# Treatment regimen\n# Primary and secondary endpoints\n## Efficacy outcomes\n## Safety and adverse events\n# Immunoscore as a biomarker","[{\"question\":\"What trial design and patient population were included?\",\"answer\":\"The study is a single-arm phase II trial enrolling 46 treatment-naïve patients with histologically confirmed LARC (T3–4N0M0 or T1–4N+M0) stratified as having intermediate or high Immunoscore and pMMR.\"},{\"question\":\"How was the treatment delivered, and when was sintilimab added?\",\"answer\":\"Patients received six cycles of mFOLFOX6 plus long-course radiotherapy (50 Gy in 25 fractions) followed by surgery. Sintilimab was added during CRT during the 2nd to 6th cycle.\"},{\"question\":\"What were the primary efficacy results?\",\"answer\":\"The primary endpoint, pathologic complete response (pCR), was 65.2% (30/46, 95% CI: 49.7–78.6), with higher pCR in high Immunoscore (85.7%) than intermediate Immunoscore (61.5%).\"},{\"question\":\"What safety outcomes were reported?\",\"answer\":\"The most common treatment-related adverse event was leukopenia (69.6%, 32/46). Grade 3 TRAEs occurred in 15.2% (7 patients), and postoperative complications occurred in four patients, all grade ≤2.\"}]","Neoadjuvant chemoradiotherapy plus sintilimab in proficient mismatch repair locally advanced rectal cancer with intermediate/high-immunoscore (SILAR) - a single-arm phase II trial | PDF",1790146825,18,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12bb935c55f803ee62dce8eaf928092c.webp",983,1305,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6420702bfcc6d62d7f7ecbf573557ab7.webp",982,1304,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d77c076c13a295b0482842e553229a05.webp",981,1303,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc5b4794ace3cd11915658d6ac69c429.webp",980,1301]